This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Labcyte Inc., a privately-held company advancing acoustic liquid handling, today announced it has closed a Series D financing led by the healthymagination fund, a part of GE Ventures. The $5.3 million round also included current Labcyte investors: Abingworth, Alloy Ventures, Cross Atlantic Partners, Delphi Ventures, H&Q Healthcare Investors (NYSE:HQH) and H&Q Life Sciences Investors (NYSE:HQL).
Labcyte will use the investment to continue to expand its revolutionary liquid handling systems based on the use of acoustic energy to precisely and accurately transfer liquids. Combined with its automation platforms and novel software capabilities, Labcyte’s award-winning products offer unsurpassed control over the steps that are the backbone of life science research, molecular medicine, drug discovery and diagnostic programs. Since acoustic dispensing transfers liquids without contact and eliminates the use of pipettes and their associated problems, data quality and reliability are significantly improved while costs are substantially reduced. The Labcyte system allows for the ability to transfer very low volumes of liquids, resulting in further cost savings by minimizing the use of reagents, while conserving precious samples. It also provides the capability to miniaturize assays and thereby increase productivity and through-put, enabling significant advances in a wide range of life science applications.
“Labcyte’s acoustic liquid handling products are well-established globally, with customers including pharmaceutical, biotechnology, diagnostic and contract research companies along with academic institutions. Our systems are being employed to further personalized medicine with multiple applications in genomics, proteomics, diagnostics and cell health,” said Mark Fischer-Colbrie, CEO and president of Labcyte. “Closing the funding will further enable us to add to our product lines and accelerate our growth.”
The investment in Labcyte reflects GE’s continuing interest in life science tools, medical diagnostics solutions and the growing area of personalized medicine. The healthymagination fund is the healthcare investing group of GE Ventures and part of GE’s $6 billion healthymagination initiative, a global commitment to deliver better health to more people.